Blood Based Eyedrops From Different Sources in the Treatment of Severe Keratopathy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03064984 |
|
Recruitment Status : Unknown
Verified February 2017 by Emilio C Campos, Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi.
Recruitment status was: Recruiting
First Posted : February 27, 2017
Last Update Posted : February 27, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Keratopathy Sjogren's Syndrome GVHD - Graft-Versus-Host Disease | Other: CBS eyedrops Other: PBS eyedrops | Not Applicable |
The rationale for the use of eye drops prepared from the blood as a source is mainly based on their content in growth factors (Growth factors, GF), which play an important role in regulation of many processes involved in normal healing of damaged corneal epithelium . The most used product so far is the eye drop prepared from serum (Autologous Serum, AS) or from platelet-rich plasma (Plasma Rich Platelet, PRP) of peripheral blood taken from the patients themselves. More recently, treatments were introduced by homologous sources that undoubtedly offer advantages as compared to autologous sources. In particular the homologous sources show:
- not invasiveness to the patient, who could in time not like the repeated withdrawals
-
applicability even in patients with underlying systemic conditions. They may contain in their blood, among others, higher levels of pro-inflammatory factors, with the consequence of poor and inappropriate final product to be prepared and delivered to the eye
- reliability, since the homologous products can be prepared, controlled, also validated under the microbiological profile and standardized advance, then kept frozen until the dispensation
- conceptually unlimited availability of the product to be dispensed
- versatility of therapeutic indications, based on different GF levels which are estimated in advance
The purpose of this study is to evaluate the effect of two products derived from two different blood sources (cord blood collected at birth from placenta umbilical veins and adult subject donor peripheral blood) in the treatment of severe keratopathies.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | This is a double-blind, interventional clinical study, randomized, multicenter. The treatments under study comprise topical products prepared from two different sources: umbilical cord blood collected at birth and adult subject donor peripheral blood. The products are prepared, standardized, controlled and sealed in anonymous frozen vials in the Transfusional Service, partner in the study. The study consists of two phases: Phase 1 is runned for one month treatment. The assignment of the treatment in Phase 1 is performed through a computer based randomization process, blind to the patient and the clinician, only known to the Transfusion Service personnel. The patient enter Phase 2 only in case of a corneal epithelial damage relapse taking place within two months after the end of Phase 1, and the treatment assigned belongs to the remaining arm. In this case also, the treatment is only known to the Transfusion Service personnel, trained to keep data aside. |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | The products under study are prepared, standardized, controlled and sealed in anonymous frozen vials in the Transfusional Service of the S.Orsola-Malpighi Hospital, our partner and collaborator in the study. The products have same physical and colour characteristics and cannot be visually recognized. Boxes containing the vials report a code of assignement only known by the Transfusion service personnel. |
| Primary Purpose: | Treatment |
| Official Title: | Blood Based Eyedrops From Different Sources in the Treatment of Severe Keratopathy - A Randomized Clinical Trial |
| Actual Study Start Date : | January 30, 2017 |
| Estimated Primary Completion Date : | June 30, 2017 |
| Estimated Study Completion Date : | September 30, 2017 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: CBS eyedrops
Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
|
Other: PBS eyedrops
PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime. |
|
Active Comparator: PBS eyedrops
Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
|
Other: CBS eyedrops
CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime. |
- Variation of corneal epithelium damage [ Time Frame: 30 days ]The effect of the treatment(s) will be evaluated by measuring the area of damaged corneal epithelium (calculated as the mm2 of damaged epithelium) after treatment as compared to baseline, and defined as 1. complete healing : no detection of damaged area; 2. Partial healing : reduction of the damaged corneal area after treatment as compared to baseline ; 3. No improvement : same damaged corneal epithelial area in mm2 at baseline and after treatment; 4. Worsening : damaged corneal epithelial area in mm2 after treatment larger than at baseline
- Variation of subjective sensation of discomfort [ Time Frame: 30 days ]The effect of the treatment(s) will be evaluated by measuring the subjective discomfort (expressed with the OSDI score) after treatment as compared to baseline and defined as 1. Disappearance of discomfort: OSDI score < 6/100; 2. Reduction of discomfort: reduction of the OSDI score after treatment as compared to baseline ; 3. No improvement : same values for OSDI score after treatment as detected in baseline; 4. Worsening : score for OSDI score after treatment higher than that detected at baseline
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of severe dry eye , scored as level severity 3 according to the Dry Eye WorkShop grade (DEWS, Ocular Surf 2007)
- corneal epithelial damage, stained with fluorescein as vital dye, NEI (national Eye Institute) score> 6 (estimated with imageJ software) damage coverage> 25% of total corneal area
- good general health condition
- ability to adhere to treatment and to the procedures provided by the study
Exclusion Criteria:
- concurrent treatment with hypotensive drugs
- ocular surgery in the 12 months preceding enrollment .
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03064984
| Contact: Emilio C Campos, MD | +39 051 2142831 | emilio.campos@unibo.it | |
| Contact: Piera Versura, BSD | +39 051 2142850 | piera.versura@unibo.it |
| Italy | |
| AOU Bologna, Ophthalmology Unit | Recruiting |
| Bologna, Italy, 40138 | |
| Contact: Emilio C Campos, MD + 390512142831 emilio.campos@unibo.it | |
| Contact: Piera Versura, BSD + 390512142850 piera.versura@unibo.it | |
| Sub-Investigator: Giuseppe Giannaccare, PhD | |
| Ospedale S.Maria Nuova - IRCCS - Ophthalmology Unit | Not yet recruiting |
| Reggio Emilia, Italy, 42123 | |
| Contact: Luigi Fontana, MD, PHD +393382060005 luigi.fontana@asmn.re.it | |
| Ospedale degli Infermi, Ophtalmology Unit | Not yet recruiting |
| Rimini, Italy, 47900 | |
| Contact: Alessandra Brancaleoni, MD +390541608692 alebranca@me.com | |
| Contact: Stefano Volanti, MD +390541608692 stefanovolanti@libero.it | |
| Principal Investigator: | Emilio C Campos, MD | AOU Bologna, University of Bologna |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Emilio C Campos, Full Professor of Ophthalmology, Head Ophthalmology Unit, University of Bologna, Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi |
| ClinicalTrials.gov Identifier: | NCT03064984 |
| Other Study ID Numbers: |
100/2016/O/Sper |
| First Posted: | February 27, 2017 Key Record Dates |
| Last Update Posted: | February 27, 2017 |
| Last Verified: | February 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Sjogren's Syndrome Graft vs Host Disease Immune System Diseases Arthritis, Rheumatoid Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Xerostomia Salivary Gland Diseases |
Mouth Diseases Stomatognathic Diseases Dry Eye Syndromes Lacrimal Apparatus Diseases Eye Diseases Connective Tissue Diseases Autoimmune Diseases Ophthalmic Solutions Pharmaceutical Solutions |